Nurix Therapeutics, Inc.

NRIX

Biotech & pharmaceuticals

$26.51vs prev close▼-0.21(-0.79%)

$8.2052W Range$28.23

91% from low

+3.34 (+14.29%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.34%

1M +0.04%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Sell)

Shares decreased, but price appreciation increased portfolio weight.

Shares -0.6% · Market value +3.9% · Weight +0.04%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.05	BUY	ARKG	43,472	$15.22	$661.6K
26.03.04	BUY	ARKG	17,347	$16.26	$282.1K
26.03.03	BUY	ARKG	84,708	$15.81	$1.3M
25.12.11	BUY	ARKG	26,928	$19.07	$513.5K
25.12.10	BUY	ARKG	11,342	$19.61	$222.4K
25.12.05	BUY	ARKG	28,227	$18.09	$510.6K
25.04.23	BUY	ARKG	104,048	$11.61	$1.2M
25.04.22	BUY	ARKG	3,242	$11.46	$37.2K
25.04.21	BUY	ARKG	12,756	$10.55	$134.6K
24.11.19	SELL	ARKG	31,143	$22.79	$709.7K
24.11.18	SELL	ARKG	8,933	$21.79	$194.7K
24.11.14	SELL	ARKG	84,253	$26.86	$2.3M
24.11.08	SELL	ARKG	23,513	$27.34	$642.8K
24.11.05	SELL	ARKG	74,130	$25.43	$1.9M
24.11.04	SELL	ARKG	24,857	$25.04	$622.4K

03.05BUY

43,472

ARKGClose$15.22Est. total$661.6K

03.04BUY

17,347

ARKGClose$16.26Est. total$282.1K

03.03BUY

84,708

ARKGClose$15.81Est. total$1.3M

12.11BUY

26,928

ARKGClose$19.07Est. total$513.5K

12.10BUY

11,342

ARKGClose$19.61Est. total$222.4K

12.05BUY

28,227

ARKGClose$18.09Est. total$510.6K

04.23BUY

104,048

ARKGClose$11.61Est. total$1.2M

04.22BUY

3,242

ARKGClose$11.46Est. total$37.2K

04.21BUY

12,756

ARKGClose$10.55Est. total$134.6K

11.19SELL

31,143

ARKGClose$22.79Est. total$709.7K

11.18SELL

8,933

ARKGClose$21.79Est. total$194.7K

11.14SELL

84,253

ARKGClose$26.86Est. total$2.3M

11.08SELL

23,513

ARKGClose$27.34Est. total$642.8K

11.05SELL

74,130

ARKGClose$25.43Est. total$1.9M

11.04SELL

24,857

ARKGClose$25.04Est. total$622.4K

1 / 3

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,677,886

Portfolio Weight

0.34%

in ETF 2.54%

Est. Value

$42M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$33.50

vs Current ▲ +25.4% upside

Current$26.72

Low ~ High$25.00 ~ $45.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

RBC Capital

Outperform

$36.00

+34.73%

—

Maintain

2026-08-10

Needham

Buy

$34.00

+27.25%

—

Maintain

2026-08-04

Morgan Stanley

Overweight

$38.00

+42.22%

—

Maintain

2026-07-28

UBS

Buy

$31.00

+16.02%

—

Maintain

2026-07-22

Mizuho

Outperform

$34.00

+27.25%

—

Maintain

2026-07-13

1 / 4

Avg Target

$33.50

vs Current ▲ +25.4% upside

Strong Buy

16 analysts

Strong Buy 5Buy 10Hold 1

Low $25.00

Current $26.72

High $45.00

Firm	Position	Target	Upside	Close	Action	Date
RBC Capital	Outperform	$36.00	+34.73%	—	Maintain	26.08.10
Needham	Buy	$34.00	+27.25%	—	Maintain	26.08.04
Morgan Stanley	Overweight	$38.00	+42.22%	—	Maintain	26.07.28
UBS	Buy	$31.00	+16.02%	—	Maintain	26.07.22
Mizuho	Outperform	$34.00	+27.25%	—	Maintain	26.07.13

1 / 4

Price Information

Previous Close$27.05

Open$27.50

Day Range$26.70 - $27.50

52-Week Range$8.20 - $28.23

1-Year Change176.32%

Trading Volume

Volume1,485,867

Avg Volume (3mo)2,020,030

Valuation

Market Cap2.8B

Book Value$3.88

Shares Outstanding103,781,683

Financials

Revenue (TTM)36.8M

Net Income-341,351,008

EPS$-3.46

EBITDA-353,180,000

Profitability

P/E Ratio-

P/B Ratio6.88

Return on Equity (ROE)-80.30%

Return on Assets (ROA)-40.06%

Profit Margin0.00%

EV/EBITDA-6.76

Beta1.79

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)77.34

Company Overview

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer and inflammatory diseases. Their main products are small molecule and antibody-based drugs, including BTK and CBL-B degraders currently in clinical trials. Nurix has established strategic collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer.

P/B

6.88

High valuation

ROE

-80.3%

Persistent loss

Beta

1.79

High volatility

RSI(14)

77.3

Overbought

AI-generated summary. Not investment advice.

Nurix Therapeutics, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks